GenBioPro, which markets a generic version of the medical abortion product, may pursue litigation in a more favorable jurisdiction than the Mississippi district court where the case had been proceeding. Senators ask HHS to consider filing its own suit to enforce federal preemption of state laws, lifting REMS restrictions and having FDA issue an EUA for misoprostol.
A legal ruling on whether US Food and Drug Administration policy preempts state laws restricting access to medication abortion has been delayed with GenBioPro Inc.’s decision to drop its suit challenging Mississippi’s laws.
GenBioPro filed a notice with the US District Court for the Southern District of Mississippi on 18 August that it has dismissed its complaint challenging Mississippi’s laws restricting access to mifepristone. The
With an FDA review ongoing, Kennedy’s admission, made during a Senate hearing on the Health and Human Services Department’s budget request, suggests political officials could supersede scientific decisions.
At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
